Bioventus (BVS) Other Non-Current Liabilities (2020 - 2026)

Bioventus (BVS) has reported Other Non-Current Liabilities for 7 consecutive years, with $13.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 37.9% year-over-year to $13.2 million; the trailing twelve-month figure through Jun 2026 stood at $13.2 million (down 37.9% YoY), and the FY2025 full-year result was $15.3 million, down 33.56% from the prior year.
• Other Non-Current Liabilities fell to $13.2 million in Q2 2026 per BVS's latest filing, from $14.3 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $81.9 million in Q4 2022 and bottomed at $13.2 million in Q2 2026.
• Historically, Other Non-Current Liabilities has averaged $26.7 million across 5 years, with a median of $23.1 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 165.04% in 2022, then slumped 62.26% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $22.8 million in 2022, then grew by 22.46% to $27.9 million in 2023, then decreased by 17.3% to $23.1 million in 2024, then sank by 33.56% to $15.3 million in 2025, then dropped by 13.91% to $13.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $13.2 million, $14.3 million, and $15.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.